Document is current

Article History

Received: 27 March 2024

Accepted: 29 October 2024

First Online: 28 March 2025

Declarations

:

: The study protocol and patient informed consent documents were approved by an institutional review board or independent ethics committee at each study site prior to initiation of the study. All patients provided written informed consent prior to participation.

: This study is registered with ClinicalTrials.gov, NCT02117219.

: Guillermo Garcia-Manero: Consulting for Genentech and Bristol-Meyers Squibb. Grants to institution from Amphivena, Novartis, AbbVie, Onconova, H3 Biomedicine, Merck, Curis, Janssen, Forty Seven, Aprea, Genentech, and Bristol-Meyers Squibb. Grants and other from Helsinn and Astex. Manila Gaddh: Advisory board for Pfizer, Agios, Hema Biologics, and Pharmacyclics LLC.Uwe Platzbecker: Grant support paid to GWT-TUD from Amgen; lecture fees and grant support, paid to the University of Leipzig; fees for serving on a steering committee, consulting fees, and travel support from Celgene; grant support paid to GWT-TUD from Janssen Biotech; grant support paid to University of Dresden from Merck and Novartis; and lecture fees from Novartis. R. Coleman Lindsley: Consulting for Bluebird Bio, Takeda Pharmaceuticals, and Jazz Pharmaceuticals. Research support from MedImmune and Jazz Pharmaceuticals. Sarah M. Larson: Research funding: Bioline, BMS, Janssen, Takeda, Celgene. Honoraria: Takeda. Consulting: BMS. Timothy Chevassut: Consultancy/honoraria for Celgene/BMS, JAZZ, Abbvie, and AstraZeneca/Medimmune. Pierre Fenaux: Honoraria and research grants (as GFM chairperson) from BMS, Janssen, Novartis, Abbvie, and Astex. Rami Komrokji: Speaker bureau for Celgene/BMS, JAZZ, Agios, and AbbVie. Consultancy/honoraria for Celgene/BMS, JAZZ, AbbVie, Agios, Acceleron, and Geron. Roger Lyons: Research and Leadership for McKesson Corp; Research support for Abbvie, Alexion, Amgen, Astra Zeneca, Bristol-Myers Squibb, Celgene, Epizyme, Gilead, Incyte, Jannsen, Karyopharm, Medimmune, Merck, Millenium, Seattle Genetics, Sunesis, Takeda, and TG Therapeutics. Aref Al-Kali: Research funding to institution from Celgene/BMS and Medimmune/AstraZeneca. John Bothos: Employee of AstraZeneca and may own stock or stock options. Danielle Townsley: Employee of AstraZeneca and may own stock or stock options. Yu Jiang: Employee of AstraZeneca and may own stock or stock options. Amer Zeidan: Amer Zeidan is a Leukemia and Lymphoma Society Scholar in Clinical Research and is also supported by a NCI’s Cancer Clinical Investigator Team Leadership Award (CCITLA). A.M.Z. received research funding (institutional) from Celgene/BMS, Abbvie, Astex, Pfizer, Medimmune/AstraZeneca, Boehringer-Ingelheim, Trovagene, Incyte, Takeda, Novartis, Aprea, and ADC Therapeutics. A.M.Z participated in advisory boards, and/or had a consultancy with and received honoraria from AbbVie, Otsuka, Pfizer, Celgene/BMS, Jazz, Incyte, Agios, Boehringer-Ingelheim, Novartis, Acceleron, Astellas, Daiichi Sankyo, Cardinal Health, Taiho, Seattle Genetics, BeyondSpring, Trovagene, Takeda, Ionis, Amgen, Janssen, Epizyme, Syndax, and Tyme. A.M.Z served on steering and independent data review committees for clinical trials for Novartis, Abbvie, and Janssen. A.M.Z received travel support for meetings from Pfizer, Novartis, and Trovagene.